Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Marker Therapeutics, Inc. | tv487788_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - Marker Therapeutics, Inc. | tv487788_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Marker Therapeutics, Inc. | tv487788_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Marker Therapeutics, Inc. | tv487788_ex31-1.htm |
| EX-10.27 - EXHIBIT 10.27 - Marker Therapeutics, Inc. | tv487788_ex10-27.htm |
| EX-4.0 - EXHIBIT 4.0 - Marker Therapeutics, Inc. | tv487788_ex4-0.htm |
| 10-K - FORM 10-K - Marker Therapeutics, Inc. | tv487788_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement of TapImmune Inc. on Form S-3 File No. 333-215258 of our report dated March 23, 2018, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of TapImmune, Inc. as of December 31, 2017 and 2016 and for the years ended, which report is included in this Annual Report on Form 10-K of TapImmune Inc. for the year ended December 31, 2017.
| /s/ Marcum LLP | |
| New York, NY | |
| March 23, 2018 |